Bris­tol My­ers, 2sev­en­ty roll out full Abec­ma da­ta in ear­li­er-stage can­cer

Bris­tol My­ers Squibb and 2sev­en­ty bio teased a top-line win for their BC­MA-tar­get­ing CAR-T Abec­ma in ear­li­er stages of mul­ti­ple myelo­ma back in Au­gust. Now they’re of­fer­ing a look at the full da­ta.

The biotech and Big Phar­ma pair put out word Fri­day that re­lapsed or re­frac­to­ry pa­tients on Abec­ma in the Kar­M­Ma-3 Phase III piv­otal tri­al saw a me­di­an 13.3 months of pro­gres­sion-free sur­vival (PFS), meet­ing the tri­al’s pri­ma­ry end­point. That’s more than the amount of time ex­pe­ri­enced by pa­tients on one of five “stan­dard reg­i­mens,” who saw a me­di­an 4.4 months of PFS (p<0.0001). The me­di­an fol­low-up time was 18.6 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.